Cellectar Biosciences Inc. receives second-phase of NCI SBIR award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cellectar Biosciences Inc. received the second phase of an NCI Fast-Track Small Business Innovation Research contract award of $2 million to support funding of a phase II study of the company’s lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma.

The award will help fund a multi-center, open label study. The first phase of the NCI SBIR contract was focused on the pre-clinical development of CLR 125.

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login